Atovaquone Patent Expiration
Atovaquone is Used for treating Pneumocystis carinii infections. It was first introduced by Glaxosmithkline Llc
Atovaquone Patents
Given below is the list of patents protecting Atovaquone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mepron |
US6649659 (Pediatric) | Atovaquone pharmaceutical compositions |
Jan 10, 2017
(Expired) | Glaxosmithkline Llc |
| Mepron | US6649659 | Atovaquone pharmaceutical compositions |
Jul 10, 2016
(Expired) | Glaxosmithkline Llc |
Atovaquone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Atovaquone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Atovaquone Combined With Radiation in Children With Malignant Brain Tumors | Emory University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults | Sanaria Inc. | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda | Medicines for Malaria Venture | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE1 |